

#### Enzymes and Chemicals: Reference Lab Case Studies

Lauren Deady, MLS (ASCP)<sup>CM</sup>


Enzymes and Chemicals: Reference Lab Case Studies

- What are the commonly used enzymes and chemicals in blood banking?
- What are their mechanisms of action?
- How do they help us identify antibodies?



### Sulfhydryl Reagents

- Dithiothreitol (DTT), 2-aminoethylisothiouronium (AET), 2-mercapto-ethanol (2-ME)
  - Cleave disulfide bonds between cysteine amino acids
    - Destroy (or weaken) KEL, YT, LU, KN, LW, JMH, IN antigens, CD38
    - Disrupt IgM intermolecular disulfide bonds
      - Treated RBCs- useful in dispersing autoagglutination
      - Treated serum/plasma- used to reduce or eliminate IgM reacting antibodies





### Ficin/Papain

- Proteolytic enzymes derived from plant sources, are cysteine endoproteases
- Cleave glycoproteins of sialic acid on the red blood cell surface altering the surface charge on the cell, reducing the zeta potential
- Denatures some blood group antigens and makes others more accessible
- Enhance adsorptive capacity of RBCs

Depressed	Variable	Enhanced
M, N; Fy <sup>a</sup> , Fy <sup>b</sup> ; Ch/Rg; XG; Bpa; IN; JMH;		Rh system; Le <sup>a</sup> , Le <sup>b</sup> ; P1; Jk <sup>a</sup> , Jk <sup>b</sup> ; Vel; I








# Trypsin

- Proteolytic enzyme
  - Serine protease that cleaves peptide chains, mainly at the carboxyl side of the amino acids lysine or arginine
  - Removes sialic acid from surface of red blood cell leading to altered surface charge
  - Causes denaturation of some antigens and increased accessibility of others





Previous anti-H in a para-Bombay autologous donor

- Donor currently pregnant, unit to be frozen in case transfusion needed during delivery
- ABO "discrepancy" and positive antibody screen need to be resolved so unit can be frozen

													0011		
	AB	O/Rh									Supplier	Additional Antigens	Pl		Patie a Tes
			Antise	era				Cells			Lot #			LI	SS
A	в	А, В	D (IS)	D Control (IS)	Weak D (IgG)	D Control (IgG)	A1	A <sub>2</sub>	В	1	Imm-Pano		ß	37	7G
3+MF	0	4+	3+	0			3+	2+	4+	2	51146 Imm-Pano 51146	é :	3+		- 3+
										3 001	Imm-Pano 51146	Co(b+)	34		- 3+
										4 001	Imm-20 51152		34	24	- 3+
												Auto ctrl	0	0	04



Antibody Screen

# Case Study 1 - Anti-H

#### **Bombay O<sub>h</sub> Phenotype**

- Rare autosomal recessive phenotype
- Homozygous for non-functioning FUT1 and FUT2 genes
- Results in absence of H, A, and/or B antigens on RBCs and in secretions
- Type as Group O, Aby screen using O cells will be positive
- Clinically significant, usually IgM

#### Para-Bombay


- Red cells lack serologically detectable levels of H antigen
- Inherited at least one functional secretor gene, leading to small amount of H, A and/or B antigens in plasma/secretions
- Weak reactions with anti-A/anti-B
- Blood types reported as A<sub>h</sub>, B<sub>h</sub>, Ab<sub>h</sub>
- Clinically significant but generally of lower titer



#### Case Study 1 – Anti-H

- Use allogeneic adsorbed plasma to resolve ABO
- Antibody screen is negative with addition of 0.01M DTT, but addition of DTT to plasma will denature any IgM reacting antibodies, so alternate methods may be needed if suspecting additional alloantibodies known to be IgM

#### ABO Serum Grouping



orbed Plas	ma
A,	B
Ó	24
	Cells A <sub>2</sub> O

#### Antibody Screen

	Supplier	Donor/			+0 Pat a T	ien	t's	
	Lot #	Vial#	IS		SS IG			
	Imm-Pano 51146	B7231 1	0	0	0	r		
	Imm-Pano 51146	C586 2	0	0	0.	-		
3 00D	Imm-Pano 51146	H1638 3	0	0	0.	-		
-	Imm-20 51152	B9607 3	0	0	0.	,		



## Case Study 1 – Anti-H

- H negative cells frozen in liquid nitrogen were thawed and tested
- Allogeneic adsorption performed to rule out anti-K
- Patient recently delivered and did not need any RBC transfusions
  Hmy frozen cells

TECH:

	D	c	E	c	e	f	Cw	v	М	N	s	s	Luª	Lub	P1	Le <sup>a</sup>	Le <sup>b</sup>	K	k	Kpª	Jsª	Fy <sup>a</sup>	Fy <sup>b</sup>	Jk <sup>a</sup>	Jk <sup>b</sup>	10	IJ	21	SS
615C	+	+	0	+	+		0		+	0	+	+	0	+	0	0	0	0	+	0		+	0	0	+		0	0	0"
6140	+	+	0	0	+		0		+	+	0	+	0	t	+	+	0	0	+	0		+	+	·+	0		0	0	0-

	D	с	E	c	e	f	v	C*	м	N	s	s	P1	Le®	Le <sup>®</sup>	Lu*	Lu <sup>b</sup>	к	k	Kp <sup>a</sup>	Js"	Fy*	۶y⁵	Jk"	Jk <sup>b</sup>			
R1R1 W20111863178600G	+	+	0	0	+				0	+	+	0	+	o	•			0				+	+	0	+			
R <sub>2</sub> R <sub>2</sub> W201118640615001	+	0	+	•_2	0				+	+	+	+	+	0	+			0				+	0	+	0			
rr W201118640613005	0	0	0	+	+	1	12		•	0	0	· +	+	+	0		1	0				0	+	0	+	IS	11. 37	ss Ige
Tr	3						-										-										-	
51152 650206	+	0	+	+	0		0	0	0	+	0	+	+	0	+	0	+	0	+	0	0	0	+	0	+	0	0	0
51152 6242 18	D	0	0	+	+		0	0	+	+.	+	0	+	0	+	0	+	+	0	0	0	+	+	0	+	0	0	0



- Patient FE is a 69 year old female, currently diagnosed with tracheal stenosis, hgb of 7.2, going to surgery STAT
- Multiple red cell transfusions, most recent was 13 days prior to current sample
- History of a cold autoantibody identified <2 weeks ago</li>
  - no underlying alloantibodies found after allogeneic adsorption
  - 3 of 4 crossmatches were compatible using tube prewarm technique




- Current sample
  - Microscopic reactions using neat plasma at LISS/IAT with 7 of 8 cells tested, negative DAT, negative autocontrol
  - RESt adsorption fails to remove reactivity, prewarm tube crossmatches are all still microscopically positive

	PANOSCREEN Master List											55																					412-11
v	IMMUCOR, INC. Norcross, GA US LICENSE NO: 886	300	071	U	SA																											_	
v	LOT NO: 51146 EXPIRES: 2018/02/23			R	h -	Hr						ł	Kell			Du	ıffy	Ki	dd	Le	wis	Ρ		М	٧		Luth- eran	Xg				RESTX	
AL	Donor	D	с	c	E	e	,	<i>.</i>	C*	к	k	Kp	Kp	Jsª	Js	Fy	Fy⁵	Jkª	Jk⁵	Le®	Le	P <sub>1</sub>	м	N	s	s L	u" Lu	⊳ Xgʻ	IS	L 37	ISS	LISS	
۱	R1R1 B7231	+	+	0	0	+	-	0	0	+	+	0	+	0	+	+	0	0	+	0	+	0	+	0	+	0	0 +	0	0	0	194	A+	
II	R2R2_C586	+	0	+	+	0	,	0	0	0	+	0	+	0	+	0	+	+	+	+	0	+	+	0	+	+	0 +	+	0	0	M+	Mt	
111	Co(b+) rr H1638	0	0	+	0	+		0	0	0	+	0	+	0	+	+	0	+	0	+	0	+	0	+	0	+	0 +	+	0	0	M	Ma	



- Current sample
  - Allogeneic adsorption at 4 C appears successful, everything is ruled out except anti-S
  - BUT, patient types S positive serologically and autocontrol/DAT are negative ruling out the presence of autoanti-S





- Treated and untreated allogeneic cells for adsorption were tried with no apparent difference in reactivity
- Now what?
  - Do titer
  - Test serum with treated reagent cells: DTT, trypsin and ficin/papain

#### Titration

Sample Date	Anti-	Phase	1	2	4	8	16	32	64	128	256	512	1024	2040 SAL CH	Titer	Score
01262018		60' Sal IG	Mt	M+	Mt	M+	Mł	Mt	Mt	Mt	M+	M+		01	1	
															3	



- 0.2M DTT treatment failed to remove reactivity
- Cells treated with Ficin and Trypsin are all negative

#### **DTT Treated Cells**

									Γ	1							T		R	hHr				MN		P	Lew	Lu	at		Ke	11		Di	af	Kid	x	1
									-		Sup	ppl Lot			Don Via		I	c	Е	c e	f	C W	м	NS	s	Pl	L L e e a b	Lua	L u b	K k	K P a	K p b	J J s s a b	Fya	Fуb	J J k k a k	g a	14
									-	1	1	F-1	18-3		317	3600	G ·	+ +	0	0 +		+	0	+ +	0	+	0 +			0		1	+	+	+	0 +	-	I
		-							-	2	A				-	1500	1	+ 0	+	+ 0		-	+	+ +	+	+	0 +		1	0	-	-	+	+	0	+ 0		1
IC	cin/Trypsin	I reated Ce	llS									F-3	18-2		2																							1
		orcross, GA 30071 U	SA							3	A DI	F-1	18-3		406 3	1300	5	0 0	0	+ +			+	0 0	+	+	+ 0	2		0				0	+	0 +	-	1
	US LICENSE NO: 880 LOT NO: 50135	0	_	a				_	L	_	-						+	+		-		-		+	+-		+	+		-	+		-	-	H	+		+
	EXPIRES: 2018/02/	16			F	Rh -	Hr						ĸ	Cell			D	uffy	K	idd	Le	wis	P		N	IN			uth- eran	>	Xg	PATI	ENT'S	SER	MET	TEST F	RESU	RT
VIAL	Special Type	Donor	D	с	c	E	e		v* c	w	к	k I	Крª	Kp⁵	Jsª	Js⁵	Fy	Fy	⊳ Jk	• Jk	Le	Le	P,	м	N	s	s	Lu	la Lu	1 <sub>P</sub> X	(g*a			4	ss		I FICI	1
		R1R1 B9454	+	+	0	0	•	-	0 0	5	0	+	0	+	0	+	+	0	+	0	0	+	0	+	0	0	+	0	+	t	÷			0			0	-
		R1wR1 B8854	+	+	0	0	•	-	0 4	·	+	+	0	+	0	+	+	+	+	+	0	+	+	Ŧ	+	+	+	0	+	T	0	2					-	ſ
		R2R2 C4676	+	0	+	+	0	,	0 0	,	+	+	0	+	0	+	0	+	+	+	0	0	+	0	+	0	+	0	+	T	0	3	0	0	M+		ď	F
4	He+	Ror D563	+	0	+	0	+	-	0 0	5	0	+	0	+	+	+	0	0	+	0	0	0	+	0	+	+	+	0	+	T	0	4		$\square$			-	Γ
5	~	r'r E1046	0	+	+	0	+	-	0 0	)	0	+	0	+	0	+	+	+	+	+	0	+	+	+	+	0	+	0	+		+	5						Γ
_		1 5000		0	+	+		-	0 0	5	0	+	0	+	0	+	+	0	0	+	0	+	+	+	0	+	0	0	+	T	+	6						
3		r"r F933	0	1.	12	1.1			- 1																													41
6		r"r F933 rr G1729	0	+	+	0	, +	t	0 0	5	+	0	0	+	0	+	0	+	0	+	0	0	0	0	+	+	+	0	+	T	0	7						Γ




Ficin/Papain	Trypsin	200mM DTT	Possible specificity
Negative	Negative	Positive	Bp <sup>a</sup> ; <b>Ch/Rg</b> ; XG; M, N, En <sup>a</sup> TS;
			Ge2,Ge4

- Chido/Rodgers Blood Group System
  - Not true blood group antigens. Located on the fourth component of complement (C4d)
  - Adsorbed onto RBC membrane from plasma
  - Clinically insignificant antibodies but have broad reactivity that can cause confusing serological results



- Identifying and characterizing Ch/Rg antibodies
  - Test with Ch/Rg negative cells
  - Test with C4 coated RBCs
  - Type for Ch/Rg antigens using hemagglutination inhibition





#### C4 coated adsorptions

- Trace amounts of C4 normally found on RBCs, leading to weak reactions with reagent cells
- Reagent red cells are coated with excess C4b or C4d by incubating with pooled normal serum (source of complement) in a sucrose solution
- Direct agglutination can be observed with Ch/Rg antibodies when incubated with coated cells
- Coated cells can also be used to adsorb anti-Ch or anti-Rg from plasma/serum
- Patient sample reacted strongly with C4 coated allogeneic cells

	Patient	Chr
Untreated Control	5' RT	5' RT
R.R.	0	0
F2R2	0	0
rr	0	0
	Patient	Cfr)
C4 coafed cells	5' RT	s' KT
R.R.	l+	M+
R2R2	24	nı
Tr	2+	M+





#### Typing for Ch/Rg by Hemagglutination Inhibition

- Direct cell typing for Ch/Rg antigens is not reliable, antigen strength is variable and may lead to false negatives
- To determine patient's phenotype, necessary to demonstrate presence or absence of the antigen in the serum

Patient	Positive control	Negative control	Saline control	Interpretation
Negative	Negative	Positive	Positive	<b>Rodgers Positive</b>
Positive	Negative	Positive	Positive	<b>Rodgers</b> Negative
Any	Positive	Any	Any	Invalid
Any	Any	Negative	Any	Invalid
Any	Any	Any	Negative	Invalid

#### **Results:**

Patient	Positive control	Negative control	Saline control	Interpretation
Positive	Negative	Positive	Positive	<b>Rodgers Negative</b>



### Case Study 2 - HTLA-like Antibody

- Patient was discharged before antibody ID was completed
- All common clinically significant antibodies were ruled out using a combination of trypsin treated RBCs, ficin treated RBCs, Rg- neat cells, and 1 non-reactive neat reagent cell at LISS/IAT
- Previous cold autoantibody not detected
- Incompatible units recommended for transfusion
- HTLAs = ⊗



- Patient ST is a 73 year old caucasian female diagnosed with UTI/flu
- 9.3 Hgb, no transfusion required
- No known RBC antibodies
- Transfused within the past 3 months, unknown pregnancy history
- Hospital reports that all cells are positive in PEG and Gel except auto control.



- Initial results: Negative DAT, panel and screen all positive at PEG and LISS IAT with a negative autocontrol
- Cold screen negative

																															ar. 17			. 1	4	C
v	LOT NO: 51146 EXPIRES: 2018/02/23	Γ		R	h -	Hr					ŀ	Kell			D	uffy	к	idd	Le	wis	Р		M	IN		Lut	3350 I	Xg					Π		5	
A		+	Γ	Г	Γ	Г	Г	Γ	┢	Γ	Γ	É					ŀ	Г	t	Γ	$\vdash$	$\vdash$			-				15'	15'				-	6	ļ
-	Donor	D	C	c	E	e	V	C~	ĸ	k	Kpʻ	Kp⁵	Jsª*	Jsb	Fy	Fy	Jk	• Jk	Le	Le	P <sub>1</sub>	М	N	S	s	Luª	Lu⁵	Xg <sup>*</sup>	4.	AT	IS	37	SS	-	7	
1	R1R1 B7231	+	+	0	0	+	0	0	+	+	0	+	0	+	+	0	0	+	0	+	0	+	0	+	0	0	+	0	0	0	0	0	1.		8	
		╈	+	┢	┢	┢	⊢	⊢	⊢	┢	⊢	┢─	-	+	$\vdash$	+	┢	┢	⊢	+	-	⊢	-	$\vdash$	-		-	-	Ľ	V	-	0	14	-	9	
1	R2R2_C586	+	0	+	+	0	0	0	0	+	0	+	0	+	0	+	+	+	+	0	+	+	0	+	+	0	+	+	0	0	0	0	1	_ ]	10	
1	Co(b+) rr H1638	0	0	+	0	+	0	0	0	+	0	+	0	+	+	0	+	0	+	0	+	0	+	0	+	0	+	+	0	0	0	0	1+		11	
	dicates those antigens whose presence or absence p	nau h	nue b		latar	mine	duci	ng of	Jura	cing		malaci	farm	aific	ntibe	. he	-		-		-				1	Lo.	-0.0"	trol	-	0	~	-	N	7 1		

An antigen designated with a 'w' represents a weakened expression of the antigen that may or may not react with all examples of the corresponding antibody.



0

Te

Cell#

0

- Next steps with this pattern of reactivity
  - Run phenotypically similar cell to determine if there are multiple alloantibodies or an antibody to high frequency antigen

С	E	С	е	Sera-clone control ABO + Rh	К	k	Fya	Fyb	Jka	Jkb	М	Ν	S	s	Lea	Leb	P1
0	0	4+	44	Mir: 8 Lat	01		2+	2+	3+	3+	3+	31	3+	3+	3+	0	4+

#### • Test serum with treated reagent cells: DTT, trypsin and ficin

	R	h -	Hr					k	Cell			Du	uffy	Ki	dd	Le	wis	Ρ		Μ	N			630 V - 1	Xg	PAT				
с	с	E	e	v	C*	к	k	Kpª	Kp⁵	Jsª"	Js⁵	Fyª	Fy⁵	Jkª	Jk⁵	Leª	Le⁵	P <sub>1</sub>	м	N	s	s	Luª	Lu <sup>b</sup>	Xg <sup>•a</sup>		LISS	100	Inpsi	7710 22.U
+	0	0	+	0	0	0	+	0	+	0	+	+	0	+	0	0	+	0	+	0	0	+	0	+	+	1	+	14	4	0
+	0	0	+	0	+	+	+	0	+	0	+	+	+	+	+	0	+	+		+	+	+	0	+	0	2				
0	+	+	0	0	0	+	+	0	+	0	+	0	+	+	+	0	0	+	0	+	0	+	0	+	0	3	1+	4	1+	Or
0	+	0	+	0	0	0	+	0	+	+	+	0	0	+	0	0	0	+	0	+	+	+	0	+	0	4				
+	+	0	+	0	0	0	+	0	+	0	+	+	+	+	+	0	+	+	+	+	0	+	0	+	+	5				
0	+	+	+	0	0	0	+	0	+	0	+	+	0	0	+	0	+	+	+	0	+	0	0	+	+	6				
0	+	0	+	0	0	÷	0	0	+	0	+	0	+	0	+	0	0	0	0	+	+	+	0	+	0	7	4	1+	1+	or
0	+	0	+	0	0	0	+	0	+	0	+	+	0	0	+	0	0	+	+	+	0	+	0	+	+	8				
0	+	0	+	0	0	0	+	0	+	0	+	0	+	+	+	+	0	+	0	+	0	+	0	+	0	9	1+	4	1+	o
0	+	0	+	0	0	0	+	0	+	0	+	0	+	0	+	+	0	+	+	0	0	+	0	+	+	10				
	+ + 0 0 + 0 0 0 0 0 0	C C + 0 + 0 0 + 0 + + + 0 + 0 + 0 + 0 + 0 +	C  C  E    +  0  0    +  0  0    0  +  +    0  +  0    +  +  0    0  +  +    0  +  0    0  +  0    0  +  0    0  +  0    0  +  0    0  +  0    0  +  0    0  +  0	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	C    C    E    e $$ +    0    0    +    0      +    0    0    +    0      0    +    +    0    0      0    +    +    0    0      0    +    0    +    0      0    +    0    +    0      0    +    0    +    0      0    +    0    +    0      0    +    0    +    0      0    +    0    +    0      0    +    0    +    0      0    +    0    +    0      0    +    0    +    0      0    +    0    +    0      0    +    0    +    0      0    +    0    +    0      0    +    0    +    0	C    c    E    e    V*    C**      +    0    0    +    0    0      +    0    0    +    0    +      0    +    +    0    0    +      0    +    +    0    0    0      0    +    0    +    0    0      0    +    0    +    0    0      0    +    0    +    0    0      0    +    0    +    0    0      0    +    0    +    0    0      0    +    0    +    0    0      0    +    0    +    0    0      0    +    0    +    0    0      0    +    0    +    0    0      0    +    0    +    0    0      0    +    0    +    0    0      0    +    0    +    0	C    C    E    e $$ Cw    K      +    0    0    +    0    0    0      +    0    0    +    0    0    +    +      0    +    +    0    0    +    +    +      0    +    +    0    0    0    +    +      0    +    0    +    0    0    0    +      0    +    0    +    0    0    0    0      +    +    0    +    0    0    0    0      0    +    0    +    0    0    0    +      0    +    0    +    0    0    0    +      0    +    0    +    0    0    0    +      0    +    0    +    0    0    0    0      0    +    0    +    0    0    0    0      0    +	C    C    E    e    V*    C**    K    k      +    0    0    +    0    0    0    +      +    0    0    +    0    0    +    +    +      0    +    +    0    0    0    +    +    +      0    +    0    0    0    0    +    +    +      0    +    0    +    0    0    0    +    +      0    +    0    +    0    0    0    +      0    +    0    +    0    0    0    +      0    +    0    +    0    0    0    +      0    +    0    +    0    0    0    +    0      0    +    0    +    0    0    0    +    0    0    +    0      0    +    0    +    0    0    0    +    0    +	C    C    E    e $\sqrt{2}$ Cw    K    k    Kp <sup>2</sup> +    0    0    +    0    0    0    +    0      +    0    0    +    0    0    +    +    0      +    0    0    +    0    0    +    +    0      0    +    +    0    0    0    +    +    0      0    +    0    +    0    0    0    +    0      0    +    0    +    0    0    0    +    0      0    +    0    +    0    0    0    +    0      0    +    +    +    0    0    0    +    0      0    +    0    +    0    0    +    0    0      0    +    0    0    0    +    0    0    +    0      0    +    0    0    0    0	C    C    E    e    V    C*    K    k    Kp <sup>a</sup> Kp <sup>b</sup> +    0    0    +    0    0    0    +    0    +      +    0    0    +    0    0    +    +    0    +      +    0    0    +    0    0    +    +    0    +      0    +    0    0    0    +    +    0    +    +    0    +      0    +    0    +    0    0    0    +    0    +    +    0    +    +    0    +	C    C    E    e    V*    C*    K    k    Kp*    Kp*    Js**      +    0    0    +    0    0    0    +    0    +    0      +    0    0    +    0    0    +    0    +    0      +    0    0    +    0    +    0    +    0    +    0      0    +    +    0    0    0    +    +    0    +    0      0    +    0    +    0    0    0    +    +    0    +    0      0    +    0    +    0    0    0    +    0    +    0      0    +    0    0    0    0    +    0    +    0      0    +    +    0    0    0    +    0    +    0      0    +    0    0    +    0    0    +    0    +    0 <td>C    C    E    e    <math>\vee^*</math>    C*    K    k    Kp*    Kp*    Js*    Js*    Js*      +    0    0    +    0    0    +    0</td> <td>C    E    e    V*    C**    K    k    Kp*    Kp*    Js**    Js*    Fy*      +    0    0    +    0    0    +    0    +    0    +    0    +    +    +    0    +    0    +    +    +    +    0    +    +    +    +    0    +    0    +    +    +    +    0    +    0    +    +    +    +    0    +    0    +    +    +    +    0    +    +    +    0    +    +    0    +    +    +    0    +    +    +    0    +    +    0</td> <td>C    C    E    e    V'    C*    K    k    Kp<sup>a</sup>    Kp<sup>b</sup>    Js<sup>a</sup>'    Js<sup>b</sup>    Fy<sup>a</sup>    Fy<sup>b</sup>      +    0    0    +    0    0    +    0    0    +    0    0    +    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +</td> <td>C    C    E    e    V°    C*    K    k    Kp°    Kp°    Js°    Js°    Fy°    Fy°    Jk°      +    0    0    +    +    0    +    0    +    0    +    0    +    0    +    +    +    0    +    +    +    0    +</td> <td>C    C    E    e    V'    C*    K    k    Kp<sup>a</sup>    Kp<sup>b</sup>    Js<sup>a</sup>    Js<sup>b</sup>    Fy<sup>a</sup>    Fy<sup>b</sup>    Jk<sup>a</sup>    Jk<sup>b</sup>      +    0    0    +    0    0    +    0    +    0    +    0    +    0    +    0    0    +    +    0    0    +    0    +    0    +    0    +    0    +    0    +</td> <td>C    C    E    e    V    C*    K    k    Kp*    Kp*    Js*    Js*    Fy*    Fy*    Jk*    Jk*    Jk*    Le*      +    0    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    0    0    0    0    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    0    0    0    0    0    0    0    0    0    +    0    +    0    +    0    +    0&lt;</td> <td>C    E    e    V*    C*    K    k    Kp°    Kp°    Js°    Js°    Fy°    Fy°    Fy°    Jk°    Jk°    Le°    Le°      +    0    0    +    0    0    +    0    0    +    0    +    0    0    +    0    0    0    +    0    0    +    0    0    +    0    0    0    <td< td=""><td>C    C    E    e    V    C*    K    k    Kp<sup>a</sup>    Kp<sup>b</sup>    Js<sup>a</sup>    Js<sup>b</sup>    Fy<sup>a</sup>    Fy<sup>b</sup>    Jk<sup>a</sup>    Jk<sup>b</sup>    Le<sup>a</sup>    Le<sup>b</sup>    P<sub>1</sub>      +    0    0    +    +    0</td><td>C    E    e    V*    C*    K    k    Kp*    Kp*    Js*    Js*    Js*    Fy*    Fy*    Jk*    Jk*    Le*    Le*    P_1    M      +    0    0    +    &lt;</td><td>C    C    E    e    V    C*    K    k    Kp*    Kp*    Js*    Js*    Fy*    Fy*    Jk*    Jk*    Le*    Le*    P_1    M    N      +    0    0    +    0</td><td>C    E    e    V    C*    K    k    Kp*    Kp*    Js*    Js*    Fy*    Fy*    Jk*    Jk*    Le*    Le*    P1    M    N    S      +    0    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    0    0    0    0    0    0    0    +    0    0    0    0    +    0    0    0    +    0    0    +    0</td><td>C    E    e    V    C*    K    k    Kp*    Kp*    Js*    Js*    Fy*    Fy*    Jk*    Le*    Le*    P1    M    N    S    S      +    0    0    +    +    +    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    0    +    0    0    0    +    0    0    +    0    0    0    0<!--</td--><td>Rn - Hr    Kell    Kell    Kell    Kell    Jsa*    Jsa*    Jsb    Fyb    Jka    Lewis    P    MiN    S    S    Lua      C    C    E    V    C*    K    k    Kpb    Jsa*    Jsb    Fyb    Jka    Jkb    Lea    Leb    P1    M    N    S    S    Lua      +    0    0    +    0    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0</td><td>C    C    E    V    C*    K    k    Kp<sup>a</sup>    Kp<sup>b</sup>    Js<sup>a</sup>    Js<sup>b</sup>    Fy<sup>b</sup>    Jk<sup>b</sup>    Le<sup>a</sup>    Le<sup>b</sup>    P<sub>1</sub>    M    N    S    S    Lu<sup>a</sup>    Lu<sup>b</sup>      +    0    0    +    0</td><td>Rn - Hr    Keit    Durry    Kidd    Lewis    P    MiN    eran    Xg      C    C    E    e    V'    C*    K    k    Kp*    Ss*    Js*    Js*</td></td></td<><td>Rh - Hr    Kell    Durry    Klod    Lewis    P    MN    eran    Ag      C    c    E    e    V<sup>*</sup>    K    k    Kp<sup>a</sup>    Sp<sup>a</sup>    Sp<sup>a</sup>    Fy<sup>a</sup>    Fy<sup>a</sup>    Jk<sup>a</sup>    Jk<sup>a</sup>    Le<sup>a</sup>    Le<sup>a</sup>    P1    M    N    S    S    Lu<sup>a</sup>    Lu<sup>b</sup>    Xg<sup>a</sup>      +    0    0    +    0    0    +    0    +    0    +    0    +    0    +    0    +    0    +    1      +    0    +    0    +    0    +    0    +    0    +    0    +    1    1    1      +    0    +    0    +    0    +    0    +    0    0    +    1</td><td>Kn - Hr    Kell    Kell    Duny    Kidd    Lews    P    MiN    eran    Xg    Treerant      C    C    E    e    V*    C*    K    k    Kp<sup>a</sup>    Js<sup>a</sup>    Js<sup>a</sup>    Fy<sup>a</sup>    Fy<sup>a</sup>    Jk<sup>a</sup>    Jk<sup>a</sup>    Le<sup>a</sup>    Le<sup>a</sup>    Le<sup>b</sup>    P1    M    N    S    S    Lu<sup>a</sup>    Xg<sup>a</sup>    Lu<sup>SS</sup>    Ju<sup>A</sup>      +    0    0    +    0    +    0    +    0    +    0    +    0    +    1    Lu<sup>S</sup>    Ju<sup>A</sup>      +    0    +    0    +    0    +    +    +    +    0    +    0    +    1    Lu<sup>S</sup>    Ju<sup>A</sup>      +    0    0    +    +    0    +    +    +    0    +    +    1    Lu<sup>S</sup>    Ju<sup>A</sup>      0    +    0    0    +    0    +    0    +    0    +    0    +    0    +    0    1    Lu<sup>S</sup>    Ju<sup>A</sup></td><td>KRI-Hr    Kell    Durry    Kild    Lewis    P    MIN    eran    Xg    TESTMETI      C    C    E    V    C*    K    k    Kp°    Kp°    Fy°    Js°    Jss    Js°    Jss    Js°    Jss    Js°    Jss    Js°    Jss    Jss    Jss    Jss    Jss    Jss    Js</td><td>Kn - Hr    Keil    Duny    Kidd    Lewis    P    MiN    eran    Xg    TESTMETHODS      C    c    E    e    V<sup>*</sup>    C*    K    k    Kp<sup>o</sup>    Js<sup>o</sup>    Fy<sup>o</sup>    Js<sup>o</sup>    Fy<sup>o</sup></td></td>	C    C    E    e $\vee^*$ C*    K    k    Kp*    Kp*    Js*    Js*    Js*      +    0    0    +    0    0    +    0	C    E    e    V*    C**    K    k    Kp*    Kp*    Js**    Js*    Fy*      +    0    0    +    0    0    +    0    +    0    +    0    +    +    +    0    +    0    +    +    +    +    0    +    +    +    +    0    +    0    +    +    +    +    0    +    0    +    +    +    +    0    +    0    +    +    +    +    0    +    +    +    0    +    +    0    +    +    +    0    +    +    +    0    +    +    0	C    C    E    e    V'    C*    K    k    Kp <sup>a</sup> Kp <sup>b</sup> Js <sup>a</sup> '    Js <sup>b</sup> Fy <sup>a</sup> Fy <sup>b</sup> +    0    0    +    0    0    +    0    0    +    0    0    +    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +	C    C    E    e    V°    C*    K    k    Kp°    Kp°    Js°    Js°    Fy°    Fy°    Jk°      +    0    0    +    +    0    +    0    +    0    +    0    +    0    +    +    +    0    +    +    +    0    +	C    C    E    e    V'    C*    K    k    Kp <sup>a</sup> Kp <sup>b</sup> Js <sup>a</sup> Js <sup>b</sup> Fy <sup>a</sup> Fy <sup>b</sup> Jk <sup>a</sup> Jk <sup>b</sup> +    0    0    +    0    0    +    0    +    0    +    0    +    0    +    0    0    +    +    0    0    +    0    +    0    +    0    +    0    +    0    +	C    C    E    e    V    C*    K    k    Kp*    Kp*    Js*    Js*    Fy*    Fy*    Jk*    Jk*    Jk*    Le*      +    0    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    0    0    0    0    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    0    0    0    0    0    0    0    0    0    +    0    +    0    +    0    +    0<	C    E    e    V*    C*    K    k    Kp°    Kp°    Js°    Js°    Fy°    Fy°    Fy°    Jk°    Jk°    Le°    Le°      +    0    0    +    0    0    +    0    0    +    0    +    0    0    +    0    0    0    +    0    0    +    0    0    +    0    0    0 <td< td=""><td>C    C    E    e    V    C*    K    k    Kp<sup>a</sup>    Kp<sup>b</sup>    Js<sup>a</sup>    Js<sup>b</sup>    Fy<sup>a</sup>    Fy<sup>b</sup>    Jk<sup>a</sup>    Jk<sup>b</sup>    Le<sup>a</sup>    Le<sup>b</sup>    P<sub>1</sub>      +    0    0    +    +    0</td><td>C    E    e    V*    C*    K    k    Kp*    Kp*    Js*    Js*    Js*    Fy*    Fy*    Jk*    Jk*    Le*    Le*    P_1    M      +    0    0    +    &lt;</td><td>C    C    E    e    V    C*    K    k    Kp*    Kp*    Js*    Js*    Fy*    Fy*    Jk*    Jk*    Le*    Le*    P_1    M    N      +    0    0    +    0</td><td>C    E    e    V    C*    K    k    Kp*    Kp*    Js*    Js*    Fy*    Fy*    Jk*    Jk*    Le*    Le*    P1    M    N    S      +    0    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    0    0    0    0    0    0    0    +    0    0    0    0    +    0    0    0    +    0    0    +    0</td><td>C    E    e    V    C*    K    k    Kp*    Kp*    Js*    Js*    Fy*    Fy*    Jk*    Le*    Le*    P1    M    N    S    S      +    0    0    +    +    +    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    0    +    0    0    0    +    0    0    +    0    0    0    0<!--</td--><td>Rn - Hr    Kell    Kell    Kell    Kell    Jsa*    Jsa*    Jsb    Fyb    Jka    Lewis    P    MiN    S    S    Lua      C    C    E    V    C*    K    k    Kpb    Jsa*    Jsb    Fyb    Jka    Jkb    Lea    Leb    P1    M    N    S    S    Lua      +    0    0    +    0    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0</td><td>C    C    E    V    C*    K    k    Kp<sup>a</sup>    Kp<sup>b</sup>    Js<sup>a</sup>    Js<sup>b</sup>    Fy<sup>b</sup>    Jk<sup>b</sup>    Le<sup>a</sup>    Le<sup>b</sup>    P<sub>1</sub>    M    N    S    S    Lu<sup>a</sup>    Lu<sup>b</sup>      +    0    0    +    0</td><td>Rn - Hr    Keit    Durry    Kidd    Lewis    P    MiN    eran    Xg      C    C    E    e    V'    C*    K    k    Kp*    Ss*    Js*    Js*</td></td></td<> <td>Rh - Hr    Kell    Durry    Klod    Lewis    P    MN    eran    Ag      C    c    E    e    V<sup>*</sup>    K    k    Kp<sup>a</sup>    Sp<sup>a</sup>    Sp<sup>a</sup>    Fy<sup>a</sup>    Fy<sup>a</sup>    Jk<sup>a</sup>    Jk<sup>a</sup>    Le<sup>a</sup>    Le<sup>a</sup>    P1    M    N    S    S    Lu<sup>a</sup>    Lu<sup>b</sup>    Xg<sup>a</sup>      +    0    0    +    0    0    +    0    +    0    +    0    +    0    +    0    +    0    +    1      +    0    +    0    +    0    +    0    +    0    +    0    +    1    1    1      +    0    +    0    +    0    +    0    +    0    0    +    1</td> <td>Kn - Hr    Kell    Kell    Duny    Kidd    Lews    P    MiN    eran    Xg    Treerant      C    C    E    e    V*    C*    K    k    Kp<sup>a</sup>    Js<sup>a</sup>    Js<sup>a</sup>    Fy<sup>a</sup>    Fy<sup>a</sup>    Jk<sup>a</sup>    Jk<sup>a</sup>    Le<sup>a</sup>    Le<sup>a</sup>    Le<sup>b</sup>    P1    M    N    S    S    Lu<sup>a</sup>    Xg<sup>a</sup>    Lu<sup>SS</sup>    Ju<sup>A</sup>      +    0    0    +    0    +    0    +    0    +    0    +    0    +    1    Lu<sup>S</sup>    Ju<sup>A</sup>      +    0    +    0    +    0    +    +    +    +    0    +    0    +    1    Lu<sup>S</sup>    Ju<sup>A</sup>      +    0    0    +    +    0    +    +    +    0    +    +    1    Lu<sup>S</sup>    Ju<sup>A</sup>      0    +    0    0    +    0    +    0    +    0    +    0    +    0    +    0    1    Lu<sup>S</sup>    Ju<sup>A</sup></td> <td>KRI-Hr    Kell    Durry    Kild    Lewis    P    MIN    eran    Xg    TESTMETI      C    C    E    V    C*    K    k    Kp°    Kp°    Fy°    Js°    Jss    Js°    Jss    Js°    Jss    Js°    Jss    Js°    Jss    Jss    Jss    Jss    Jss    Jss    Js</td> <td>Kn - Hr    Keil    Duny    Kidd    Lewis    P    MiN    eran    Xg    TESTMETHODS      C    c    E    e    V<sup>*</sup>    C*    K    k    Kp<sup>o</sup>    Js<sup>o</sup>    Fy<sup>o</sup>    Js<sup>o</sup>    Fy<sup>o</sup></td>	C    C    E    e    V    C*    K    k    Kp <sup>a</sup> Kp <sup>b</sup> Js <sup>a</sup> Js <sup>b</sup> Fy <sup>a</sup> Fy <sup>b</sup> Jk <sup>a</sup> Jk <sup>b</sup> Le <sup>a</sup> Le <sup>b</sup> P <sub>1</sub> +    0    0    +    +    0	C    E    e    V*    C*    K    k    Kp*    Kp*    Js*    Js*    Js*    Fy*    Fy*    Jk*    Jk*    Le*    Le*    P_1    M      +    0    0    +    <	C    C    E    e    V    C*    K    k    Kp*    Kp*    Js*    Js*    Fy*    Fy*    Jk*    Jk*    Le*    Le*    P_1    M    N      +    0    0    +    0	C    E    e    V    C*    K    k    Kp*    Kp*    Js*    Js*    Fy*    Fy*    Jk*    Jk*    Le*    Le*    P1    M    N    S      +    0    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    0    0    0    0    0    0    0    +    0    0    0    0    +    0    0    0    +    0    0    +    0	C    E    e    V    C*    K    k    Kp*    Kp*    Js*    Js*    Fy*    Fy*    Jk*    Le*    Le*    P1    M    N    S    S      +    0    0    +    +    +    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    +    0    0    0    +    0    0    0    +    0    0    +    0    0    0    0 </td <td>Rn - Hr    Kell    Kell    Kell    Kell    Jsa*    Jsa*    Jsb    Fyb    Jka    Lewis    P    MiN    S    S    Lua      C    C    E    V    C*    K    k    Kpb    Jsa*    Jsb    Fyb    Jka    Jkb    Lea    Leb    P1    M    N    S    S    Lua      +    0    0    +    0    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0</td> <td>C    C    E    V    C*    K    k    Kp<sup>a</sup>    Kp<sup>b</sup>    Js<sup>a</sup>    Js<sup>b</sup>    Fy<sup>b</sup>    Jk<sup>b</sup>    Le<sup>a</sup>    Le<sup>b</sup>    P<sub>1</sub>    M    N    S    S    Lu<sup>a</sup>    Lu<sup>b</sup>      +    0    0    +    0</td> <td>Rn - Hr    Keit    Durry    Kidd    Lewis    P    MiN    eran    Xg      C    C    E    e    V'    C*    K    k    Kp*    Ss*    Js*    Js*</td>	Rn - Hr    Kell    Kell    Kell    Kell    Jsa*    Jsa*    Jsb    Fyb    Jka    Lewis    P    MiN    S    S    Lua      C    C    E    V    C*    K    k    Kpb    Jsa*    Jsb    Fyb    Jka    Jkb    Lea    Leb    P1    M    N    S    S    Lua      +    0    0    +    0    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0    +    0	C    C    E    V    C*    K    k    Kp <sup>a</sup> Kp <sup>b</sup> Js <sup>a</sup> Js <sup>b</sup> Fy <sup>b</sup> Jk <sup>b</sup> Le <sup>a</sup> Le <sup>b</sup> P <sub>1</sub> M    N    S    S    Lu <sup>a</sup> Lu <sup>b</sup> +    0    0    +    0	Rn - Hr    Keit    Durry    Kidd    Lewis    P    MiN    eran    Xg      C    C    E    e    V'    C*    K    k    Kp*    Ss*    Js*    Js*	Rh - Hr    Kell    Durry    Klod    Lewis    P    MN    eran    Ag      C    c    E    e    V <sup>*</sup> K    k    Kp <sup>a</sup> Sp <sup>a</sup> Sp <sup>a</sup> Fy <sup>a</sup> Fy <sup>a</sup> Jk <sup>a</sup> Jk <sup>a</sup> Le <sup>a</sup> Le <sup>a</sup> P1    M    N    S    S    Lu <sup>a</sup> Lu <sup>b</sup> Xg <sup>a</sup> +    0    0    +    0    0    +    0    +    0    +    0    +    0    +    0    +    0    +    1      +    0    +    0    +    0    +    0    +    0    +    0    +    1    1    1      +    0    +    0    +    0    +    0    +    0    0    +    1	Kn - Hr    Kell    Kell    Duny    Kidd    Lews    P    MiN    eran    Xg    Treerant      C    C    E    e    V*    C*    K    k    Kp <sup>a</sup> Js <sup>a</sup> Js <sup>a</sup> Fy <sup>a</sup> Fy <sup>a</sup> Jk <sup>a</sup> Jk <sup>a</sup> Le <sup>a</sup> Le <sup>a</sup> Le <sup>b</sup> P1    M    N    S    S    Lu <sup>a</sup> Xg <sup>a</sup> Lu <sup>SS</sup> Ju <sup>A</sup> +    0    0    +    0    +    0    +    0    +    0    +    0    +    1    Lu <sup>S</sup> Ju <sup>A</sup> +    0    +    0    +    0    +    +    +    +    0    +    0    +    1    Lu <sup>S</sup> Ju <sup>A</sup> +    0    0    +    +    0    +    +    +    0    +    +    1    Lu <sup>S</sup> Ju <sup>A</sup> 0    +    0    0    +    0    +    0    +    0    +    0    +    0    +    0    1    Lu <sup>S</sup> Ju <sup>A</sup>	KRI-Hr    Kell    Durry    Kild    Lewis    P    MIN    eran    Xg    TESTMETI      C    C    E    V    C*    K    k    Kp°    Kp°    Fy°    Js°    Jss    Js°    Jss    Js°    Jss    Js°    Jss    Js°    Jss    Jss    Jss    Jss    Jss    Jss    Js	Kn - Hr    Keil    Duny    Kidd    Lewis    P    MiN    eran    Xg    TESTMETHODS      C    c    E    e    V <sup>*</sup> C*    K    k    Kp <sup>o</sup> Js <sup>o</sup> Fy <sup>o</sup>



Ficin	Trypsin	200mM DTT	Possible specificity
Positive	Positive	Negative	LW, KEL
Positive	Positive	Weak	CROM
Variable	Positive	Weak or Negative	ΥT

																																		2	X	X	X	2	3	L	L	l		-	Ę.	ţ	ıt	ıt	at	u	u	n,	1	Ŀ	I	1						1	8	1	1	1	N	N	IN	11	41	M	M	P	1										2	P	1		1	W	V	9	e	4	I	ł	d	5	i	Č.	ķ	5	f	u	21	D							5	1	11	1	2	ζe	K	3				
	Addi Anti																								5	ő	đ	3						Ŧ	g	x ga	9	9	5			l	4	1	a	L u b	u	υ	1	Ŀ		ι	ı	L u a	ι		2	1	3	8	2	5					s	S	S	20		-		1	Ŋ	N	N	)		I	M	M		1000 Contractor	-	P1	1 to beau			b				m m L.			Jkb	ł	- 11	s	0 X C	7	Fyb			Fya		5	Jsb	1 51	 	J s a				K pb	1.1		R p a	1	c	k		X
																																		)	0	0	0	0	1						+	+	+	+	1		000	P.	)	0	C				+	+	4					+	+	+	+		100			)	c	0	C	-			+	+			)	0	(		)	0	(	10000		+	+		0	(	Ī	÷	+	2	C		t	+	2									0	1.5		+		ł	+		D
																																			+	+	+	+	1.00					N.	+	+	+	+			5		Đ	+	+				+	+	+				1	)	0	0	0	(	1000				t	+	+	1.4			0	C		20		+			)	0	(	5555	1	0	C	10.000	ŧ	0.0		ł	+	)	C		)	0	1000		0	(		+	T.		+	+		)	0	10.000	t.	+		C
-	Yt( Do	-			-	-	-	-		-	-	. •	. •	2																L D	L D				0	0	C	(	1		Ī	Ī		-	+	+	+	+				F	)	0	0				ł	+	+					+	+	+	+		10			-	+	+	+	0			+	+			-	+			)	0	(	1 SNS		+	+		0	(		ł	+	2	C		ł	+									ł	+	-	)	0	0000	)	0		+
			)	)	)	)	)		)					5	)	)	)		-	2	b	k	(]	(	1	1	u	U	A	A	A	7	1							T	t	t	1	1							T					1							t	1								T	1					1	T				ľ	1				I				Γ	1						T					t				1						t			ľ			ľ			Ť	1



#### Case Study 3 – Anti-Yt<sup>a</sup>

- The YT blood group system
  - Two allele system, no inherited Yt(a-b-) individuals have been identified.
  - YT antigens are found within the enzyme acetylcholinesterase. The function of this enzyme on RBC membranes is unknown.
  - Occurrence of Yt<sup>a</sup> antigen is >99.8% in most populations
  - Clinical significance of anti-Yt<sup>a</sup> is variable, antigen negative units may not be required



	D	С	E	c	e	f	C"	v	М	N	s	s	Lu <sup>a</sup>	Lu <sup>b</sup>	P <sup>1</sup>	Leª	Le <sup>b</sup>	К	k	- Kp <sup>a</sup>	Js*	Fy <sup>a</sup>	Fyð	Jk <sup>a</sup>	Лк <sup>b</sup>	1/ta	LISS IAT
5400	+	+	0	+	+				+	0	0	+						+	+			+	0	+	+	0	0"
5690	0	0	0	+	+		0		+	0	+	0	0	+	+	0	+	0	+	0	-	+	+	+	+	0	0~
5220	+	+	0	+.	+			0	+	+	+	0						+	+			0	+	+	0	0	0-



#### Conclusions

# Enzymes and chemicals are invaluable in a reference blood bank

- Remove strong IgM reactivity to look for underlying IgG alloantibodies
- Narrow down suspects in suspected high frequency antibody identifications
- Identify and characterize HTLA-like antibodies
- Rule out alloantibodies in complex antibody identifications



#### References

- Beattie, K., Crawford, M., Mallory, D., & Mougey, R. (1993). *Immunohematology Methods and Procedures*. Rockville, MD: American Red Cross National Reference Laboratory.
- Daniels, Geoff. (2013). Human Blood Groups. Hoboken, NJ: John and Wiley Sons.
- Fernandes, Heloise Pöckel, Cesar, Carlos Lenz, & Barjas-Castro, Maria de Lourdes. (2011). Electrical properties of the red blood cell membrane and immunohematological investigation. *Revista Brasileira de Hematologia e Hemoterapia*, 33(4), 297-301.
- Judd, J. W., Johnson, S. T., & Storry, J.R. (2008). Judd's Methods in Immunohematology. Bethesda, MD: AABB Press.
- Reid, M. E., & Lomas-Francis, C. (1997). *The Blood Group Antigen: Factsbook*. San Diego: Academic Press.
- Storry, Jill R. "Other Blood Group Systems and Antigens." *Technical Manual*. 19th ed. Bethesda, MD: AABB, 2017. 319-348.
- Westman, J.S., & Olsson, M.L. "ABO and Other Carbohydrate Blood Group Systems." *Technical Manual*. 19th ed. Bethesda, MD: AABB, 2017. 265-294

